The adaptive design of the I-SPY2 study allowed for the rapid evaluation of novel drugs in combination with neoadjuvant chemotherapy (NAC) compared with NAC alone.
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
A new study describes how the flu vaccine creates an antitumoral response in mouse models of metastatic melanoma that has spread to the lungs.
The rarity of lung sarcomatoid carcinoma has limited specific investigations of the safety and efficacy of ICIs in patients with this disease.
The new risk score, developed by Emory researchers, could be a useful tool for determining overall and progression-free survival after immunotherapy.
Researchers aimed to identify clinicopathologic characteristics of patients with stage III melanoma who would benefit from regular CNS imaging.
Certain immune-mediated pathways may facilitate pulmonary impairment and lung cancer etiology.
Fewer treatment-related grade 3 or higher adverse events were reported in the avelumab arm compared with the chemotherapy arm.
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
Research presented at SITC 2019 looks at 2 different mechanisms for resistance to immune checkpoint inhibition in pancreatic ductal adenocarcinoma.
